Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase EARLY_PHASE1 1Phase 1/2 1

Status

Unknown 10Recruiting 9Completed 6Not yet recruiting 5Active not recruiting 2

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Conditions

Breast Neoplasms 544Neoplasms 384Carcinoma, Non-Small-Cell Lung 325Colorectal Neoplasms 296Lung Neoplasms 237Prostatic Neoplasms 220Carcinoma, Hepatocellular 213Stomach Neoplasms 155Pancreatic Neoplasms 155Leukemia, Myeloid, Acute 141Uterine Cervical Neoplasms 132Multiple Myeloma 130Recurrence 120Rectal Neoplasms 114Ovarian Neoplasms 109Neoplasm Metastasis 105Squamous Cell Carcinoma of Head and Neck 98Head and Neck Neoplasms 91Triple Negative Breast Neoplasms 87Esophageal Neoplasms 84Glioblastoma 82Endometrial Neoplasms 80Small Cell Lung Carcinoma 79Brain Neoplasms 79Colonic Neoplasms 78Melanoma 71Precursor Cell Lymphoblastic Leukemia-Lymphoma 65Hematologic Neoplasms 65Glioma 63Disease 60

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Not yet recruiting × Advanced Malignant Tumors × Clear all
NCT07409766 2026-02-13

A Phase I Platform Study of Target-Based Screened CAR-Macrophages for the Treatment of Advanced Malignant Tumors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase EARLY_PHASE1 Not yet recruiting
20 enrolled

Advanced Malignant Tumors

NCT07338838 2026-01-14

To Evaluate the Tolerability and Pharmacokinetics of TQB3142 for Injection in Patients With Advanced Malignant Tumors

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 1 Not yet recruiting
66 enrolled

Advanced Malignant Tumors

NCT06770881 2025-01-13

JSKN033 in Chinese Subjects with Advanced Malignant Tumors

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Phase 1/2 Not yet recruiting
430 enrolled

Advanced Malignant Tumors

NCT06691360 2024-11-15

AK137 (Bispecific Antibody Targeting CD73 and LAG-3) in Patients With Advanced Malignant Tumors

Akeso

Phase 1 Not yet recruiting
87 enrolled

Advanced Malignant Tumors

NCT06226363 2024-01-26

Phase I Study of LNF1901 in Advanced Malignant Tumors

Shandong New Time Pharmaceutical Co., LTD

Phase 1 Not yet recruiting
82 enrolled

Advanced Malignant Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡